Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cellular Senescence and Frailty
Author(s): Jorge D Erusalimsky Added: 1 week ago

Prevention & Chronic Conditions

CV Disease in Special Populations
Immune Cell Traits and Aortic Dissection: A Mendelian Randomisation Study
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 1 year ago

Electrophysiology & Arrhythmia

Inherited and Congenital Cardiac Conditions
Erratum: Causal Characteristics of Immune Cells
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 11 months ago
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Author(s): Wei Gao , Hui Wang , Jian-long Wang , et al Added: 5 months ago

Demographic

Heart Failure
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 1 year ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure
Author(s): Fatin Fazrina Roslan , Yuexin Yu , Nurul Ain Nasim Mohd Yusof , et al Added: 1 year ago

Anticoagulation
Emerging Toxicities, Translational Research and Reverse Cardio-oncology
Author(s): Massimiliano Camilli , Luca Maggio , Lorenzo Tinti , et al Added: 1 year ago

CV Disease in Special Populations

Heart Failure
Autophagy and Endoplasmic Reticulum Stress in HFpEF
Author(s): Citrawati Dyah Kencono Wungu , Hendri Susilo , Cleodylon Reinard Susanto , et al Added: 1 month ago

MI/ACS

Prevention & Chronic Conditions
Frailty in Cardio-oncology
Author(s): Ilaria Torre , Lorenzo Tinti , Ludovica Amore , et al Added: 2 months ago

CV Disease in Special Populations

Heart Failure
Semaglutide May Aid Vascular Repair in High-Risk Patients
Added: 3 weeks ago Source:  Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹… View more

Cardiovascular Renal Metabolic